

REVIEW

Open Access



Equine trypanosomosis: enigmas and diagnostic challenges

Philippe Büscher^{1*} , Mary Isabel Gonzatti², Laurent Hébert³, Noboru Inoue⁴, Ilaria Pascucci⁵, Achim Schnauffer⁶, Keisuke Suganuma⁴, Louis Touratier⁷ and Nick Van Reet¹

Abstract

Equine trypanosomosis is a complex of infectious diseases called dourine, nagana and surra. It is caused by several species of the genus *Trypanosoma* that are transmitted cyclically by tsetse flies, mechanically by other haematophagous flies, or sexually. *Trypanosoma congolense* (subgenus *Nannomonas*) and *T. vivax* (subgenus *Dutonella*) are genetically and morphologically distinct from *T. brucei*, *T. equiperdum* and *T. evansi* (subgenus *Trypanozoon*). It remains controversial whether the three latter taxa should be considered distinct species. Recent outbreaks of surra and dourine in Europe illustrate the risk and consequences of importation of equine trypanosomosis with infected animals into non-endemic countries. Knowledge on the epidemiological situation is fragmentary since many endemic countries do not report the diseases to the World Organisation for Animal Health, OIE. Other major obstacles to the control of equine trypanosomosis are the lack of vaccines, the inability of drugs to cure the neurological stage of the disease, the inconsistent case definition and the limitations of current diagnostics. Especially in view of the ever-increasing movement of horses around the globe, there is not only the obvious need for reliable curative and prophylactic drugs but also for accurate diagnostic tests and algorithms. Unfortunately, clinical signs are not pathognomonic, parasitological tests are not sufficiently sensitive, serological tests miss sensitivity or specificity, and molecular tests cannot distinguish the taxa within the *Trypanozoon* subgenus. To address the limitations of the current diagnostics for equine trypanosomosis, we recommend studies into improved molecular and serological tests with the highest possible sensitivity and specificity. We realise that this is an ambitious goal, but it is dictated by needs at the point of care. However, depending on available treatment options, it may not always be necessary to identify which trypanosome taxon is responsible for a given infection.

Keywords: Equine, Dourine, Nagana, Surra, Diagnosis, *Trypanosoma brucei*, *Trypanosoma congolense*, *Trypanosoma equiperdum*, *Trypanosoma evansi*, *Trypanosoma vivax*

Background

Equine trypanosomosis is a complex of infectious diseases called dourine, nagana and surra that are caused by several closely related species of *Trypanosoma*. They give rise to important economic losses in Africa, the Middle East, Asia and Latin America. Nevertheless, they can be considered as animal diseases that are seriously neglected, both by the scientific community as by veterinary authorities and regulatory organisations.

The situation is aggravated by the reluctance of many endemic countries to notify dourine and surra to the World Organisation for Animal Health. Major obstacles to the local and global control of equine trypanosomosis are the lack of vaccines, the inability of drugs to cure the neurological stage of the infections, the inconsistent case definitions and the limitations of current diagnostics. Recent outbreaks of surra and dourine in Europe illustrate the risk and consequences of importation of equine trypanosomosis with infected animals into non-endemic countries. In view of the ever-increasing movement of horses around the globe, there is not only the obvious need for reliable curative and prophylactic drugs but also for accurate diagnostic tests and algorithms. The

*Correspondence: pbuscher@itg.be

¹ Department of Biomedical Sciences, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium

Full list of author information is available at the end of the article



aim of this article is to provide an overview of the existing knowledge on the aetiology of equine trypanosomosis and the taxonomic status of the infecting trypanosomes, the geographical distribution, prevention and treatment options and diagnostic tools. We further discuss the issue of imperfect case definitions and propose research to address the limitations of current diagnostics.

Aetiology

Equine trypanosomosis is an infectious disease that is caused by several species of the genus *Trypanosoma*, including *T. evansi*, *T. equiperdum*, *T. brucei*, *T. vivax*, *T. congolense* and *T. cruzi*. Infections of horses with *T. cruzi* are very rare and are not further considered here [1]. Historically, the diseases caused by these trypanosomes are called “surra” (*T. evansi*), “dourine” (*T. equiperdum*) and “nagana” (*T. brucei*, *T. congolense* and *T. vivax*) but careful examination of published and unpublished data reveals that for all these three diseases, the clinical signs observed, including ventral oedema, emaciation, anaemia and neurological symptoms, can be very similar and are certainly not pathognomonic [2–7].

Transmission and resulting geographical distribution

Trypanosoma brucei and *T. congolense* are the only species that are confined to the distribution of tsetse flies (the vector) in sub-Saharan Africa. *Trypanosoma equiperdum* is transmitted sexually, and *T. evansi* is transmitted mechanically by blood-sucking flies, vampire bats, and possibly sexually [8, 9].

Oral transmission of *T. evansi* via contaminated meat or carcasses is well documented but normally does not occur in equines [10, 11]. *Trypanosoma vivax* can be transmitted both cyclically by tsetse flies and mechanically by other haematophagous flies. The global distribution of *T. equiperdum*, *T. evansi* and *T. vivax* is much wider, including Africa and Latin America for *T. vivax*, Africa, Latin America and Asia with sporadic import cases in Europe for *T. evansi* and worldwide, except Oceania, for *T. equiperdum* [12, 13]. Most countries where trypanosomosis are endemic do not regularly report on these diseases, and as a consequence, the exact burden and area of distribution remain largely unknown. For example, a systematic review on surra shows serious discrepancy between countries reporting this disease to the World Organisation for Animal Health (OIE) and countries for which published evidence of surra exist [12]. From recent reviews on surra it becomes clear that its distribution map is based on anecdotal observations [12–15]. No such recent reviews exist on *T. brucei*, *T. congolense*, *T. equiperdum* and *T. vivax* in horses. However, evidence is increasingly being published on horses

infected with *T. evansi*, *T. equiperdum* and *T. vivax* in Brazil, Ethiopia, India, Israel, Jordan, Mongolia, Nigeria, Pakistan, South East Asia, Sudan, Venezuela, etc. [12, 13, 16–25].

Prevention and treatment

Vaccines against equine trypanosomosis do not exist. Chemotherapy of equine trypanosomosis consists of treatment with diminazene diaceturate, isometamidium chloride, quinapyramine chloride/quinapyramine sulphate combination, suramin or melarsomine hydrochloride. Except for trypanosome strains that display an innate or acquired resistance, these drugs are able to clear the parasites from the blood circulation [26]. However, except for *T. congolense*, all the other trypanosomes are known to reside mainly in extravascular spaces of many tissues and organs, including the central nervous system. Evidence is accumulating that none of the aforementioned drugs is effective in the neurological stage of the disease since none is able to cross the blood-brain-barrier in sufficient amounts [24, 27–30]. Still, a recent outbreak of surra (caused by *T. evansi*) in Spain was brought under control upon treatment with melarsomine hydrochloride (Cymelarsan, Merial, France) of all parasitologically confirmed and suspect animals (dromedary camels, horses, donkeys) as well as of all animals that were in direct or indirect contact with the index case [31]. The latter was a dromedary camel imported from Gran Canaria, without prior screening for surra, one-and-a-half years before the disease was detected [31, 32]. Another outbreak, this time of dourine (caused by *T. equiperdum*), occurred in Italy in 2011 and illustrates the risk of importation of equine trypanosomosis with infected animals into non-endemic countries [33]. That outbreak was only brought under control thanks to drastic measures taken by the veterinary authorities over several years [6, 33, 34]. A potential, yet undocumented, risk of importation of equine trypanosomosis into non-endemic countries is by artificial insemination with contaminated semen [7].

Taxonomy and morphology

Trypanosoma congolense (subgenus *Nannomonas*) and *T. vivax* (subgenus *Duttonella*) are species that are clearly separated, both genetically and morphologically, from the other taxa within the genus *Trypanosoma*. On the other hand, whether *T. brucei*, *T. equiperdum* and *T. evansi*, traditionally grouped together under the subgenus *Trypanozoon*, can be considered distinct species remains controversial. Morphologically, *T. brucei* can be distinguished from the latter two taxa by its pleomorphic nature with long slender, intermediate and short stumpy trypomastigote forms present in the mammalian host. The short stumpy forms are those that will initiate

infection in the vector of nagana, the tsetse fly [5]. *Trypanosoma equiperdum* and *T. evansi* are monomorphic and display only long slender forms, although in *T. evansi*, intermediate forms may sometimes be found [35]. Lack of monophyly of *T. equiperdum* and *T. evansi*, and the fact that genetic differences to *T. brucei* are small, have led to proposals that they should be classified as subspecies or strains of *T. brucei* [35–38]. Other studies have proposed that many so-called *T. equiperdum* isolates are in fact misidentified *T. evansi* strains, and that *T. evansi* and *T. equiperdum* evolved separately and on more than one occasion from *T. brucei* [38–41]. Today, based on kinetoplast minicircle differences, *T. evansi* is further divided into *T. evansi* type A and type B, the latter so far only isolated from camels in eastern Africa [42]. The “true” (i.e. non-controversial) *T. equiperdum* strains can be divided in at least two and maybe more clades of distinct evolutionary origin [38, 41]. Newly isolated *T. equiperdum* strains from outbreaks in Italy and in Mongolia may even further complicate the taxonomic situation [6, 16]. Table 1 summarises the major characteristics of *Trypanosoma* taxa that may cause trypanosomosis in equines.

Diagnosis

Diagnosis of equine trypanosomosis can be challenging due to the absence of specific clinical signs, and because parasitaemias in infected hosts are usually below the detection limit of parasitological tests and can even be below the detection limit of molecular DNA tests [33]. Therefore, diagnosis heavily relies on the combination of

clinical signs, serological evidence of infection and epidemiological context. Importantly, where several species co-exist, mixed infections may be frequent [43, 44].

Clinical diagnosis

Clinical signs of nagana, dourine and surra vary with disease stage (acute, chronic, neurological stage), infecting strain and variable intra- and inter-species susceptibility of the host.

For example, donkeys can carry an infection without developing classical signs of the diseases [45]. Typical, but not pathognomonic, are pyrexia, anaemia, ventral and genital oedema, urticarial plaques, conjunctivitis and keratitis, etc. [5, 28, 46–48]. In the neurological phase of infection with *T. brucei*, *T. equiperdum* or *T. evansi*, ataxia and paralysis of the hind quarter and lips usually precede death. The clinical course of the disease and long-term outcome depend on the parasite strain involved and the immunological status of the host. Other equine diseases that share some clinical signs with trypanosomosis are equine viral arteritis, equine infectious anaemia, contagious equine metritis, anthrax [5].

Parasitological diagnosis

For microscopic parasitological diagnosis, the most common biological fluid examined is blood, but parasites may be detected in lymph aspirated from superficial lymph nodes, cerebrospinal fluid, milk and vaginal or preputial discharges [6, 16, 49, 50]. In principle, it is possible to distinguish *T. vivax* and *T. congolense* from the *Trypanozoon* species based on morphology, but this is not evident for

Table 1 Overview of some characteristics of different taxa within the genus *Trypanosoma* causing equine trypanosomosis

	<i>Trypanozoon</i>			<i>Duttonella</i>	<i>Nannomonas</i>
	<i>T. brucei</i>	<i>T. evansi</i> type A	<i>T. equiperdum</i>	<i>T. vivax</i>	<i>T. congolense</i>
Distribution	Sub-Saharan Africa	Africa, Latin America, Middle East, Asia	Worldwide except Oceania USA and Canada	Africa, Latin America	Sub-Saharan Africa
Mammalian host range	Multi-species	Multi-species	Equines	Multi-species	Multi-species
Transmission	Tsetse	Biting flies, vampire bats, orally (sexually?)	Sexually (orally via milk?)	Tsetse, biting flies	Tsetse
Morphology in the mammalian host	Pleomorphic ^a	Monomorphic ^b	Monomorphic	Monomorphic	Monomorphic
Kinetoplast	Complete	Dyskinetoplastic ^c or akinetoplastic ^d	Dyskinetoplastic	Complete or dyskinetoplastic	Complete
Kinetoplast minicircle type		A	C or undefined		
ATPase γ C-terminus mutations		A281-	A273P or WT		

^a Pleomorphic: present as long slender, short stumpy and intermediate trypomastigotes during an infection

^b Monomorphic: long slender trypomastigotes with anecdotal evidence for partial pleomorphism in *T. evansi* [35]

^c Dyskinetoplastic: partial loss of kinetoplast DNA, in particular maxicircle DNA

^d Akinetoplastic: complete lack of kinetoplast DNA

the species within the subgenus *Trypanozoon*. In case of a microscopic trypanosome-positive specimen, species identification is best performed with a combination of molecular tests that have also the advantage of having a lower detection limit than microscopic parasite detection and that are able to detect mixed infections that may remain cryptic by microscopic examination [43].

Molecular diagnosis

A plethora of molecular diagnostic tests has been described which target DNA sequences that are specific at different taxonomic levels and which use diverse technology. The most commonly used test formats are polymerase chain reaction (PCR) and quantitative PCR (qPCR). The 18S and ITS1 sequences within the ribosomal DNA (rDNA) locus as well as satellite DNA are preferential targets for species-specific molecular diagnostics because of their multi-copy nature and the possibility to discriminate the taxa of the subgenus *Trypanozoon* from *T. congolense* and *T. vivax* [16, 51–54]. Distinguishing the taxa within *Trypanozoon* is more challenging. PCR tests based on the mitochondrial DNA of these parasites (kinetoplast DNA or kDNA) can potentially distinguish *T. evansi* and some *T. equiperdum* from *T. brucei* by the absence of the maxicircle component of kDNA, and identify *T. evansi* type B by presence of the type B minicircle [42, 55, 56]. However, many *T. evansi* strains are naturally akinetoplastic (i.e. complete lack of kDNA) so that molecular tests targeting kDNA have limited value. Some authors claim that *T. evansi* type A can be identified by the presence of the type A-specific RoTat 1.2 variant surface glycoprotein (VSG) gene and *T. evansi* type B by the presence of the type B-specific JN 2118HU VSG [57–59]. However, both are single-copy genes which inherently limits the analytical sensitivity of PCRs based on these VSGs and their absence in the genome of *T. brucei* has not been investigated extensively. Furthermore, the VSG repertoire is subject to recombination and therefore inherently unstable, and other researchers have shown that some Kenyan *Trypanozoon* isolates with type A minicircles appear to lack the RoTat 1.2 gene, while the JN 2118Hu VSG gene was also found in *T. b. gambiense* type II [56, 60]. Unfortunately, today there is no simple molecular test that is able to distinguish *T. brucei* from *T. equiperdum*, which means that the epidemiological context has to be taken into account to identify the trypanosome species in an infected horse.

Serological diagnosis

In contrast to *T. congolense* and, to a lesser extent, *T. vivax*, *Trypanozoon* trypanosomes are primarily tissue parasites; parasitaemia is often very low and seldom reaches the threshold of current parasitological or even

molecular diagnostic tests, especially in asymptomatic carriers. Therefore, antibody detection tests are available and can provide indirect evidence of infection.

The complement fixation test (CFT) and the indirect fluorescence antibody test (IFAT) are the only OIE recommended tests for *T. equiperdum* infection [61]. For *T. evansi* infection, OIE recommends IFAT, an enzyme linked immunosorbent assay (ELISA/RoTat 1.2), a card agglutination test for trypanosomosis using *T. evansi* antigen (CATT/*T. evansi*) and immune trypanolysis (IT) [62]. For infections with *T. brucei*, *T. vivax* and *T. congolense*, OIE recommends using IFAT and ELISA [63].

The IT test detects exclusively antibodies that recognise one single multi-copy epitope at the surface of the RoTat 1.2 VSG expressing *T. evansi* type A [64]. As a result, the specificity of IT test is extremely high, but the disadvantages of the test are its complexity and its inability to detect antibodies against other trypanosomes. The CATT/*T. evansi* test is a direct agglutination test that makes use of the same *T. evansi* RoTat 1.2 clone used in the IT test, but the preparation of the reagent exposes other surface antigens as well, resulting in some cross-reactivity with *T. vivax* and *T. equiperdum* [49, 65, 66]. Lower cross-reactivity is expected in the ELISA/RoTat 1.2 with purified VSG RoTat 1.2 as antigen.

Other serological tests use crude preparations derived from bloodstream form trypomastigotes grown *in vivo* (mice or rats) or propagated *in vitro* [67, 68]. The CFT test for dourine, using whole cell extracts from a *T. equiperdum* strain, has the advantage that it, to a certain level, also reacts with antibodies against *T. evansi*; however, this also entails the risk of false positive reactions [67]. Since *T. equiperdum* infection is considered non-curable, any false positive reaction will have serious consequences (castration, isolation, slaughtering of CFT positive animals). Reactivity of CFT with horses infected with *T. brucei*, or even with *T. congolense* or *T. vivax*, seems possible but remains undocumented. An additional problem with CFT is that reactivity may vary in function of the trypanosome strain used to prepare the antigen and of the VSG expressed by the trypanosomes at the moment of harvesting. Efforts to harmonise the antigen preparation of CFT in the diverse laboratories around the world are challenged by the fact that, within the subgenus *Trypanozoon*, genetic distinction between *T. equiperdum*, *T. evansi* and *T. brucei* is blurred, as discussed above [38, 40, 41, 60, 69, 70]. Among scientist members of the OIE Non-Tsetse Transmitted Animal Trypanosomoses Network [71], the consensus is that the Onderstepoort Veterinary Institute (OVI) strain can be adopted as reference strain for *T. equiperdum* for the purpose of CFT antigen preparation. It is this strain that is now used by the European Reference Laboratory for Equine Diseases

in France, the National Reference Laboratory for Dourine in Germany and the USDA National Veterinary Services Laboratories [67, 68]. New Mongolian *T. equiperdum* isolates have not been fully typed; whether they may serve as reference strains for the Asian region remains to be investigated [16].

Similar to the CFT, the trypanosome strains used for IFAT and ELISA for *T. evansi* (other than RoTat 1.2), *T. brucei*, *T. vivax* and *T. congolense* have not been defined. Furthermore, as a result of antigenic variation, it is not possible to control the particular VSG that is expressed at the moment of antigen preparation. Since this VSG accounts for 10% of the protein content of a bloodstream form trypomastigote, it is a major, yet undefined, component of crude antigen preparations for IFAT and ELISA. Other proteins in crude trypanosome antigen preparations may cross-react with antibodies unrelated to infection with trypanosomes [72].

Inconsistent case definitions

Case definitions with unequivocal criteria to identify a case of dourine, surra and nagana are essential to estimate the impact of these diseases on the horse population, to guide surveillance, control and prevention strategies, and to choose among treatment options, the latter taking into account that treatment success is largely dependent on the stage of the diseases rather than on the infecting trypanosome strain. An attempt at such case definition was made during the dourine outbreak in Italy in 2011; subsequently, the same case definition was adopted by the OIE Terrestrial Manual [6, 33]. According to this definition, a case of dourine is considered confirmed when an animal has a positive result with CFT, IFA or PCR, and (i) shows clinical signs compatible with dourine; (ii) shows an increase in serological CFT titre in two consecutive tests; or (iii) is epidemiologically linked with a confirmed case of dourine [33, 61, 73]. An important limitation to consider here is that this case definition only fully applies if (i) dourine as a disease is exclusively caused by *Trypanozoon* parasites that can be reliably distinguished from *T. brucei* and *T. evansi* and (ii) if CFT, IFAT and PCR exist that are fully specific for these parasites. Unfortunately, both conditions are not fulfilled.

According to the OIE Terrestrial Manual [62], an equid is negative to surra if it is negative to ELISA-*T. evansi* (anti-horse IgG whole molecule), CATT/*T. evansi*, PCR-TBR (i.e. PCR targeting *Trypanozoon*-specific satellite DNA [54]) and microscopic examination. An equid is considered infected with *Trypanozoon spp.* (*sic*) if it is positive to PCR-TBR and/or if *Trypanozoon* parasites are observed by microscopic examination. An equid is considered as seropositive to surra if it is positive to ELISA-*T. evansi* and/or CATT/*T. evansi*; in this case, the animal

should be tested for CFT-dourine, and, if it is positive for CFT-dourine, it is also considered as seropositive to dourine; if it is negative to CFT-dourine, it is considered as seropositive to surra only [62]. This “composite” case definition takes into account inherent difficulties to distinguish the *Trypanozoon* taxa, but the definition of seropositivity is questionable and does not take into account possible cross-reactions with *T. brucei*, *T. vivax* and *T. congolense*. It also disregards the possibility to use more specific tests such as the IT and the ELISA/RoTat 1.2 to rule out or suggest infection with *T. evansi* type A. Both may miss *T. evansi* type B infections, but *T. evansi* type B has so far only been isolated from dromedary camels in Kenya and Ethiopia [55, 56].

For equine infections with *T. brucei*, *T. vivax* and *T. congolense*, the OIE Terrestrial Manual does not provide any case definition.

How can the limited specificity of current diagnostics for equine trypanosomosis that impedes international movement of competition horses be addressed?

In order to improve the specificity of diagnostics for equine trypanosomosis, the focus should be on molecular and serological tests.

Molecular tests can identify with relatively high sensitivity and excellent specificity *T. congolense*, *T. vivax* and *Trypanozoon* taxa. However, within *Trypanozoon*, no single test is able to identify each taxon unequivocally. On the other hand, for the purpose of international movement of horses, it seems sufficient to use a combination of genus- and subgenus-specific molecular tests. As qPCR is becoming the standard now, the conventional PCR tests might be transformed into qPCR to improve standardisation and sensitivity. In any case, given the usually low parasitaemia in clinically healthy, yet infected, equines, the negative predictive value of molecular tests is inherently low.

Regarding serological tests, improvements are possible with respect to test format and antigens. CFT and IFAT should be replaced by techniques that are less complex and easier to standardise, such as ELISA for high throughput or immunochromatography for individual testing. Important to keep in mind, however, is the market failure that prevents commercial companies to invest in the development of such tests. The diagnostic specificity of antibody detection tests is largely defined by the antigen preparation. Therefore, the use of crude antigen preparations should be discouraged, and initiatives to replace them with recombinant or synthetic peptides should be supported. For *T. congolense* and *T. vivax*, recombinant fragments of respectively Cathepsin B1 and the cytoskeleton associated

protein GM6 are used in the VeryDiag test [74]. Also, recombinant *T. vivax* Cathepsin L has some diagnostic potential [75]. For the species of subgenus *Trypanozoon*, many common proteins have already been expressed as recombinant antigens with proven diagnostic potential, in particular the invariant surface glycoproteins 65 and 75 (ISG65, ISG75), the cytoskeleton associated protein GM6 and, more recently, a *T. equiperdum* protein that exhibits homology with the regulatory subunit of mammalian cAMP-dependent protein kinases [76–86]. None of them, however, have been evaluated for their diagnostic accuracy in *Trypanozoon* infections in general, irrespective of the infecting trypanosome species and geographical origin. In case there is a need to detect *T. evansi* type A specific antibodies, a recombinant fragment of VSG RoTat 1.2, expressed in different systems, has shown its diagnostic potential [80, 87–89].

Conclusions

To address the limitations of the current diagnostics for equine trypanosomiasis we recommend not to aim for the distinction between taxa within the subgenus *Trypanozoon*. We propose to conduct studies into (i) improved molecular tests with the highest possible sensitivity; and (ii) improved serological tests with the highest possible specificity. For the proper evaluation of these diagnostics, it will be necessary to establish a panel of representative trypanosome strains, and their corresponding DNA/RNA, as well as a panel of biological specimens (serum/plasma/blood) from horses naturally or experimentally infected with *T. vivax*, *T. congolense* and representative *Trypanozoon* taxa.

Abbreviations

18S: 18 Svedberg unit; ATP: adenosine triphosphate; cAMP: cyclic adenosine monophosphate; CATT: card agglutination test for trypanosomiasis; CFT: complement fixation test; IFAT: indirect fluorescence antibody test; IgG: immunoglobulin G; ISG: invariant surface glycoprotein; ITS1: internal transcribed spacer 1; kDNA: kinetoplast DNA; OIE: Office International des Epizooties, World Organisation for Animal Health; OVI: Onderstepoort Veterinary Institute; PCR: polymerase chain reaction; qPCR: quantitative PCR; rDNA: ribosomal DNA; RNA: ribonucleic acid; RoTat: Rhode *Trypanosoma* antigen type; TBR: *Trypanosoma brucei* repetitive satellite DNA sequence; USDA: United States Department of Agriculture; VSG: variant surface glycoprotein; WT: wild type.

Acknowledgements

Not applicable.

Funding

AS is supported by Senior Non-Clinical Fellowship MR/L019701/1 from the UK Medical Research Council. NVR is supported by the Bill & Melinda Gates Foundation OPP1174221-2018. The funding bodies had no role in the concept and writing of the manuscript.

Availability of data and materials

Not applicable.

Authors' contributions

NV and PB conceived the review. AS, IP, KS, LH, LT, MIG, NI, NV, PB contributed to the writing of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Department of Biomedical Sciences, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium. ² Departamento de Biología Celular, Universidad Simón Bolívar, Caracas 1080, Venezuela. ³ PhEED Unit, Animal Health Laboratory in Normandy, ANSES, 14430 Goustranville, France. ⁴ Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido 080-8555, Japan. ⁵ Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "G. Caporale", Campo Boario, 64100 Teramo, Italy. ⁶ Centre for Immunity, Infection and Evolution, Institute of Immunology and Infection Research, University of Edinburgh, Charlotte Auerbach Road, Edinburgh EH9 3FL, UK. ⁷ Consultant member of the OIE Non-Tsetse Transmitted Animal Trypanosomiasis Network, Bordeaux, France.

Received: 31 October 2018 Accepted: 6 May 2019

Published online: 15 May 2019

References

- Bryan LK, Hamer SA, Shaw S, Curtis-Robles R, Auckland LD, Hodo CL, et al. Chagas disease in a Texan horse with neurologic deficits. *Vet Parasitol*. 2016;216:13–7.
- Taylor K, Authié E. Pathogenesis of animal trypanosomiasis. In: Maudlin I, Holmes P, Miles MA, editors. *The trypanosomiasis*. 1st ed. Wallingford: CABI Publishing; 2004. p. 331–53.
- Mc Cully RM, Neitz WO. Clinicopathological study on experimental *Trypanosoma brucei* infections in horses. Part 2. Histopathological findings in the nervous system and other organs of treated and untreated horses reacting to Nagana. *Onderstepoort J Vet Res*. 1971;38:141–76.
- Neitz WO, Mc Cully RM. Clinicopathological study on experimental *Trypanosoma brucei* infections in horses. Part 1. Development of clinically recognizable nervous symptoms in Nagana-infected horses treated with subcurative doses of antrypol and berenil. *Onderstepoort J Vet Res*. 1971;38:127–40.
- Van den Bossche P. Equine trypanosomiasis. In: Mair TS, Hutchinson RS, editors. *Infectious diseases of the horse*. Fordham: Equine Veterinary Journal Ltd.; 2009. p. 345–65.
- Pascucci I, Di Provvido A, Camara C, Di Francesco G, Calistri P, Tittarelli M, et al. Diagnosis of dourine outbreaks in Italy. *Vet Parasitol*. 2013;193:30–8.
- Ahmed Y, Hagos A, Merga B, Van Soom A, Duchateau L, Goddeeris B, et al. *Trypanosoma equiperdum* in the horse—a neglected threat? *Vlaams Diergeneesk Tijdschr*. 2018;87:66–75.
- Wang ZL. The similarities and differences of the characteristics between *T. equiperdum* and *T. evansi*. *Bull Vet Col*. 1988;8:300–3.
- Uche UE, Jones TW. Pathology of experimental *Trypanosoma evansi* infection in rabbits. *J Comp Pathol*. 1992;106:299–309.
- Raina AK, Kumar R, Sridhar VSR, Singh RP. Oral transmission of *Trypanosoma evansi* infection in dogs and mice. *Vet Parasitol*. 1985;18:67–9.
- Sinha PK, Mukherjee GS, Das MS, Lahiri RK. Outbreak of trypanosomiasis evansi amongst tigers and jaguars in the zoological garden, Calcutta. *Indian Vet J*. 1971;48:306–10.
- Aregawi WG, Agga GE, Abdi RD, Büscher P. Systematic review and meta-analysis on the global distribution, host range, and prevalence of *Trypanosoma evansi*. *Parasit Vectors*. 2019;12:67.
- Giordani F, Morrison LJ, Rowan TG, de Koning HP, Barrett MP. The animal trypanosomiasis and their chemotherapy: a review. *Parasitology*. 2016;143:1862–89.

14. Desquesnes M, Dargantes A, Lai DH, Lun ZR, Holzmüller P, Jittapalpong S. *Trypanosoma evansi* and surra: a review and perspectives on transmission, epidemiology and control, impact, and zoonotic aspects. *BioMed Res Int*. 2013;2013:321237.
15. Desquesnes M, Holzmüller P, Lai DH, Dargantes A, Lun ZR, Jittapalpong S. *Trypanosoma evansi* and surra: a review and perspectives on origin, history, distribution, taxonomy, morphology, hosts, and pathogenic effects. *BioMed Res Int*. 2013;2013:194176.
16. Suganuma K, Narantsatsral S, Battur B, Yamasaki S, Otgonsuren D, Musinguzi SP, et al. Isolation, cultivation and molecular characterization of a new *Trypanosoma equiperdum* strain in Mongolia. *Parasit Vectors*. 2016;9:481.
17. Sánchez E, Perrone T, Recchimuzzi G, Cardozo I, Biteau N, Aso PM, et al. Molecular characterization and classification of *Trypanosoma* spp. Venezuelan isolates based on microsatellite markers and kinetoplast maxicircle genes. *Parasit Vectors*. 2015;8:536.
18. Birhanu HA, Fikru R, Said M, Kidane W, Gebrehiwot T, Hagos A, et al. Epidemiology of *Trypanosoma evansi* and *Trypanosoma vivax* in domestic animals from selected districts of Tigray and Afar regions, North Ethiopia. *Parasit Vectors*. 2015;8:212.
19. Fikru R, Hagos A, Alemu T, Claes F, Goddeeris BM. Comparative diagnostic sensitivity of parasitological, serological and PCR tests in dourine suspected horses. *Trop Anim Health Prod*. 2010;42:1649–54.
20. Hagos A. Equine trypanosomiasis in Ethiopia: epidemiology, characterization and control. PhD Thesis, Katholieke Universiteit Leuven; 2010.
21. Schmitt Nunes JT, Schafer da Silva A, de Souza Dorneles F, Tonin AA, Lazzarotto C, Miletti LC, et al. Occurrence of *Trypanosoma evansi* in horses in the state of Minas Gerais, Brazil. *J Equine Vet Sci*. 2012;32:205–7.
22. Alsam A, Chaudhary ZI, Rehman H, Ashraf K, Ahmad N, Maqbool A, et al. Comparative evaluation of parasitological, serological and DNA amplification methods for diagnosis of natural trypanosomal infection in equines. *Pak Vet J*. 2010;42:371–6.
23. Ul Hasan M, Muhammad G, Gutierrez C, Iqbal Z, Shakoor A, Jabbar A. Prevalence of *Trypanosoma evansi* infection in equines and camels in the Punjab region, Pakistan. *Ann N Y Acad Sci*. 2006;1081:322–4.
24. da Silva AS, Garcia Perez HA, Costa MM, Franca RT, De GD, Zanette RA, et al. Horses naturally infected by *Trypanosoma vivax* in southern Brazil. *Parasitol Res*. 2011;108:23–30.
25. Salim B, Bakheit MA, Sugimoto C. Molecular detection of equine trypanosomes in the Sudan. *Vet Parasitol*. 2014;200:246–50.
26. Mekonnen G, Mohammed EF, Kidane W, Nesibu A, Yohannes H, Van RN, et al. Isometamidium chloride and homidium chloride fail to cure mice infected with Ethiopian *Trypanosoma evansi* type A and B. *PLoS Negl Trop Dis*. 2018;12:e0006790.
27. Cauchard J, Carnicer D, Madeline A, Guitton E, Giraudet A, Büscher P, et al. Evaluation of melarsamine hydrochloride (Cymelarsan) efficacy for the treatment of dourine. *J Equine Vet Sci*. 2016;39:551.
28. Auty H, Mundy A, Fyumagwa RD, Picozzi K, Welburn S, Hoare R. Health management of horses under high challenge from trypanosomes: a case study from Serengeti, Tanzania. *Vet Parasitol*. 2008;154:233–41.
29. Ranjithkumar M, Saravanan BC, Yadav SC, Kumar R, Singh R, Dey S. Neurological trypanosomiasis in quinapyramine sulfate-treated horses—a breach of the blood–brain barrier? *Trop Anim Health Prod*. 2014;46:371–7.
30. Hébert L, Guitton E, Madeline A, Géraud T, Zientara S, Laugier C, et al. Melarsamine hydrochloride (Cymelarsan®) fails to cure horses with *Trypanosoma equiperdum* OVI parasites in their cerebrospinal fluid. *Vet Parasitol*. 2018;264:47–51.
31. Tamarit A, Gutierrez C, Arroyo R, Jimenez V, Zagala G, Bosch I, et al. *Trypanosoma evansi* infection in mainland Spain. *Vet Parasitol*. 2010;167:74–6.
32. Gutierrez C, Desquesnes M, Touratier L, Büscher P. *Trypanosoma evansi*: recent outbreaks in Europe. *Vet Parasitol*. 2010;174:26–9.
33. Calistri P, Narcisi V, Atzeni M, De Massis F, Tittarelli M, Mercante MT, et al. Dourine reemergence in Italy. *J Equine Vet Sci*. 2013;33:83–9.
34. Dominguez M, Munstermann S, de Guindos I, Timoney P. Equine disease events resulting from international horse movements: systematic review and lessons learned. *Equine Vet J*. 2015;48:642–53.
35. Hoare CA. The trypanosomes of mammals. Oxford: Blackwell Scientific Publications; 1972.
36. Lai D-H, Hashimi H, Lun Z-R, Ayala FJ, Lukes J. Adaptations of *Trypanosoma brucei* to gradual loss of kinetoplast DNA: *Trypanosoma equiperdum* and *Trypanosoma evansi* are petite mutants of *T. brucei*. *Proc Natl Acad Sci USA*. 2008;105:1999–2004.
37. Wen YZ, Lun ZR, Zhu XQ, Hide G, Lai DH. Further evidence from SSCP and ITS DNA sequencing support *Trypanosoma evansi* and *Trypanosoma equiperdum* as subspecies or even strains of *Trypanosoma brucei*. *Infect Genet Evol*. 2016;41:56–62.
38. Carnes J, Anupama A, Balmer O, Jackson A, Lewis M, Brown R, et al. Genome and phylogenetic analyses of *Trypanosoma evansi* reveal extensive similarity to *T. brucei* and multiple independent origins for dyskinetoplasty. *PLoS Negl Trop Dis*. 2015;9:e3404.
39. Claes F, Agbo EC, Radwanska M, te Pas MFW, Baltz T, De Waal DT, et al. How does *Trypanosoma equiperdum* fit into the Trypanozoon group? A cluster analysis by RAPD and multiplex-endonuclease genotyping approach. *Parasitology*. 2003;126:425–31.
40. Claes F, Büscher P, Touratier L, Goddeeris BM. *Trypanosoma equiperdum*: master of disguise or historical mistake? *Trends Parasitol*. 2005;21:316–21.
41. Cuypers B, Van den Broeck F, Van Reet N, Meehan CJ, Cauchard J, Wilkes JM, et al. Genome-wide SNP analysis reveals distinct origins of *Trypanosoma evansi* and *Trypanosoma equiperdum*. *Genome Biol Evol*. 2017;9:1990–7.
42. Borst P, Fase-Fowler F, Gibson WC. Kinetoplast DNA of *Trypanosoma evansi*. *Mol Biochem Parasitol*. 1987;23:31–8.
43. Pinchbeck GL, Morrison LJ, Tait A, Langford J, Meehan L, Jallow S, et al. Trypanosomiasis in The Gambia: prevalence in working horses and donkeys detected by whole genome amplification and PCR, and evidence for interactions between trypanosome species. *BMC Vet Res*. 2008;4:7.
44. Faye D, Pereira de Almeida P, Goossens B, Osaer S, Ndao M, Berkvens D, et al. Prevalence and incidence of trypanosomiasis in horses and donkeys in the Gambia. *Vet Parasitol*. 2001;101:101–14.
45. Rodrigues CM, Batista JS, Lima JM, Freitas FJ, Barros IO, Garcia HA, et al. Field and experimental symptomless infections support wandering donkeys as healthy carriers of *Trypanosoma vivax* in the Brazilian Semiarid, a region of outbreaks of high mortality in cattle and sheep. *Parasit Vectors*. 2015;8:564.
46. Brun R, Hecker H, Lun Z-R. *Trypanosoma evansi* and *T. equiperdum*: distribution, biology, treatment and phylogenetic relationship. *Vet Parasitol*. 1998;79:95–107.
47. Poursines Y, Pigoury L, Borde R, Bernard M. Trypanosomose expérimentale du cheval à *Trypanosoma evansi* (Souche Syrienne). 1. Etude clinique. *Bull Soc Pathol Exot*. 1943;36:235–44.
48. Hébert L, Guitton C, Madeline A, Géraud B, Carnicer D, Lakhdar L, et al. Validation of a new experimental model for assessing drug efficacy against infection with *Trypanosoma equiperdum* in horses. *Vet Parasitol*. 2018;263:27–33.
49. Hagos A, Abebe G, Büscher P, Goddeeris BM, Claes F. Serological and parasitological survey of dourine in the Arsi-Bale highlands of Ethiopia. *Trop Anim Health Prod*. 2010;42:769–76.
50. Pascucci S, Bettini P, Prati A, Vecchi G, Carboni A. Isolation of a trypanosome from a mare with dourine. *Atti Soc Ital Sci Vet*. 1977;31:793–4.
51. Desquesnes M, McLaughlin G, Zoungrana A, Dávila AM. Detection and identification of *Trypanosoma* of African livestock through a single PCR based on internal transcribed spacer 1 of rDNA. *Int J Parasitol*. 2001;31:610–4.
52. Geysen D, Delespau V, Geerts S. PCR-RFLP using Ssu-rDNA amplification as an easy method for species-specific diagnosis of *Trypanosoma* species in cattle. *Vet Parasitol*. 2003;110:171–80.
53. Njiru ZK, Constantine CC, Guya S, Crowther J, Kiragu JM, Thompson RC, et al. The use of ITS1 rDNA PCR in detecting pathogenic African trypanosomes. *Parasitol Res*. 2005;95:186–92.
54. Masiga DK, Smyth AJ, Hayes P, Bromidge TJ, Gibson WC. Sensitive detection of trypanosomes in tsetse flies by DNA amplification. *Int J Parasitol*. 1992;22:909–18.
55. Njiru ZK, Constantine CC, Masiga DK, Reid SA, Thompson RC, Gibson WC. Characterization of *Trypanosoma evansi* type B. *Infect Genet Evol*. 2006;6:292–300.

56. Birhanu HA, Gebrehiwot T, Goddeeris BM, Büscher P, Van Reet N. New *Trypanosoma evansi* type B isolates from Ethiopian dromedary camels. *PLoS Negl Trop Dis*. 2016;10:e0004556.
57. Claes F, Radwanska M, Urakawa T, Majiwa P, Goddeeris B, Büscher P. Variable surface glycoprotein RoTat 1.2 PCR as a specific diagnostic tool for the detection of *Trypanosoma evansi* infections. *Kinetoplastid Biol Dis*. 2004;3:1–6.
58. Konnai S, Mekata H, Mingala CN, Abes NS, Gutierrez CA, Herrera JR, et al. Development and application of a quantitative real-time PCR for the diagnosis of Surra in water buffaloes. *Infect Genet Evol*. 2009;9:449–52.
59. Ngaira JM, Olembo NK, Njagi ENM, Ngeranwa J. The detection of non-RoTat 1.2 *Trypanosoma evansi* infection (surra). 2012. http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.05.03_DOURINE.pdf. Accessed 18 Oct 2018.
60. Kamidi CM, Saarman NP, Dion K, Mireji PO, Ouma C, Murilla G, et al. Multiple evolutionary origins of *Trypanosoma evansi* in Kenya. *PLoS Negl Trop Dis*. 2017;11:e0005895.
61. OIE. Manual of diagnostic tests and vaccines for terrestrial animals. Chapter 2.5.3. Dourine. 2013. http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.05.03_DOURINE.pdf. Accessed 18 Oct 2018.
62. OIE. Manual of diagnostic tests and vaccines for terrestrial animals. Chapter 2.1.17. *Trypanosoma evansi* infection (surra). 2012. http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.01.21_TRYPANO_SURRA.pdf. Accessed 18 Oct 2018.
63. OIE. Manual of diagnostic tests and vaccines for terrestrial animals. Chapter 2.4.18. Trypanosomiasis (including tsetse-transmitted, but excluding surra and dourine). 2018. http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.04.17_TRYPANOSOMOSIS.pdf. Accessed 18 Oct 2018.
64. Verloo D, Magnun E, Büscher P. General expression of RoTat 1.2 variable antigen type in *Trypanosoma evansi* isolates from different origin. *Vet Parasitol*. 2001;97:183–9.
65. Van Vlaenderen G. In search of cattle trypanosomiasis in Suriname. MSc Thesis, Prince Leopold Institute of Tropical Medicine, Antwerp; 1996.
66. Claes F, Ilgekbayeva GD, Verloo D, Saidouldin TS, Geerts S, Büscher P, et al. Comparison of serological tests for equine trypanosomiasis in naturally infected horses from Kazakhstan. *Vet Parasitol*. 2005;131:221–5.
67. Cauchard J, Soldan A, Madeline A, Johnson P, Büscher P, Petry S. Inter-laboratory ring trials to evaluate serological methods for dourine diagnosis. *Vet Parasitol*. 2014;205:70–6.
68. Bassarak B, Moser I, Menge C. *In vitro* production of *Trypanosoma equiperdum* antigen and its evaluation for use in serodiagnosis of dourine. *Vet Parasitol*. 2016;223:133–40.
69. Perrone TM, Gonzatti MI, Villamizar G, Escalante A, Aso PM. Molecular profiles of Venezuelan isolates of *Trypanosoma* sp. by random amplified polymorphic DNA method. *Vet Parasitol*. 2009;161:194–200.
70. Zablotskij VT, Georgiu C, de Waal T, Clausen PH, Claes F, Touratier L. The current challenges of dourine: difficulties in differentiating *Trypanosoma equiperdum* within the subgenus *Trypanozoon*. *Rev Sci Tech Off Int Epizoot*. 2003;22:1087–96.
71. OIE Non Tsetse Transmitted Animal Trypanosomiasis Network. 2017. <http://www.oie.int/nttat/index.html>. Accessed 18 Oct 2018.
72. Luciani M, Di FT, Orsini M, Krasteva I, Cattaneo A, Podaliri VM, et al. *Trypanosoma equiperdum* low molecular weight proteins as candidates for specific serological diagnosis of dourine. *Front Vet Sci*. 2018;5:40.
73. Scacchia M, Camma C, Di FG, Di PA, Giunta R, Luciani M, et al. A clinical case of dourine in an outbreak in Italy. *Vet Ital*. 2011;47:473–5.
74. Boulangé A, Pillay D, Chevtzoff C, Biteau N, de Graça VC, Rempeters L, et al. Development of a rapid antibody test for point-of-care diagnosis of animal African trypanosomiasis. *Vet Parasitol*. 2017;233:32–8.
75. Eysen EA, Vather P, Jackson L, Ximba P, Biteau N, Baltz T, et al. Recombinant and native *TviCATL* from *Trypanosoma vivax*: enzymatic characterisation and evaluation as a diagnostic target for animal African trypanosomiasis. *Mol Biochem Parasitol*. 2018;223:50–4.
76. Dessalegn M. Study of the invariant surface glycoprotein ISG65 in the *Trypanozoon* subgenus. MSc Thesis, Katholieke Universiteit Leuven, Institute of Tropical Medicine; 2004.
77. Tran T, Claes F, Dujardin J-C, Büscher P. The invariant surface glycoprotein ISG75 gene family consists of two main groups in the *Trypanozoon* subgenus. *Parasitology*. 2006;133:613–21.
78. Tran T, Büscher P, Vandenbussche G, Wyns L, Messens J, De Greve H. Heterologous expression, purification and characterisation of the extracellular domain of trypanosome invariant surface glycoprotein ISG75. *J Biotechnol*. 2008;135:247–54.
79. Tran T, Claes F, Verloo D, De Greve H, Büscher P. Towards a new reference test for surra in camels. *Clin Vaccine Immunol*. 2009;16:999–1002.
80. Rogé S, Van Reet N, Odiwuor S, Tran T, Schildermans K, Vandamme S, et al. Recombinant expression of trypanosome surface glycoproteins in *Pichia pastoris* for the diagnosis of *Trypanosoma evansi* infection. *Vet Parasitol*. 2013;197:571–9.
81. Rogé S. Development of new serodiagnostic tests for African trypanosomiasis due to *Trypanosoma evansi* and *Trypanosoma brucei gambiense*. PhD Thesis, University of Antwerp; 2015.
82. Thuy NT, Goto Y, Lun ZR, Kawazu SI, Inoue N. Tandem repeat protein as potential diagnostic antigen for *Trypanosoma evansi* infection. *Parasitol Res*. 2012;110:733–9.
83. Nguyen TT, Zhou M, Ruttayaporn N, Nguyen QD, Nguyen VK, Goto Y, et al. Diagnostic value of the recombinant tandem repeat antigen TeGM6-4r for surra in water buffaloes. *Vet Parasitol*. 2014;201:18–23.
84. Nguyen TT, Motsiri MS, Taiwo MO, Mthali MS, Goto Y, Kawazu S, et al. Application of crude and recombinant ELISAs and immunochromatographic test for serodiagnosis of animal trypanosomiasis in the Umkhanyakude district of Kwazulu-Natal province, South Africa. *J Vet Med Sci*. 2015;77:220.
85. Davaasuren B, Amgalanbaatar T, Musinguzi SP, Suganuma K, Otgonsuren D, Mossaad E, et al. The evaluation of GM6-based ELISA and ICT as diagnostic methods on a Mongolian farm with an outbreak of non-tsetse transmitted horse trypanosomiasis. *Vet Parasitol*. 2017;244:123–8.
86. Mendoza E, Bubis J, Perez-Rojas Y, Montilla AJ, Spencer LM, Bustamante F, et al. High immunological response against a *Trypanosoma equiperdum* protein that exhibits homology with the regulatory subunits of mammalian cAMP-dependent protein kinases. *J Immunol*. 2018;39:451–69.
87. Lejon V, Claes F, Verloo D, Maina M, Urakawa T, Majiwa P, et al. Recombinant RoTat 1.2 variable surface glycoprotein for diagnosis of *Trypanosoma evansi* in dromedary camel. *Int J Parasitol*. 2005;35:455–60.
88. Rogé S, Baelmans R, Claes F, Lejon V, Guisez Y, Jacquet D, et al. Development of a latex agglutination test with recombinant variant surface glycoprotein for serodiagnosis of surra. *Vet Parasitol*. 2014;205:460–5.
89. Birhanu H, Rogé S, Simon T, Baelmans R, Gebrehiwot T, Goddeeris BM, et al. Surra Sero K-SeT, a new immunochromatographic test for serodiagnosis of *Trypanosoma evansi* infection in domestic animals. *Vet Parasitol*. 2015;211:153–7.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.